STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (347,581)	$ (1,309,497)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	102,905	34,520
Gain on sale of equipment	(2,179)	0
Provision for bad debt	0	2,137
Write down of other receivables	0	115,913
Write down of advanced royalties	0	77,905
Share-based compensation	41,814	181,365
Unrealized (gain) loss on stock price guarantee	(46,179)	358,850
Changes in assets and liabilities:
Accounts receivable	896	62,741
Other receivables	0	4,425
Inventories	0	1,305
Prepaid expenses and other current assets	50,753	20,850
Advanced royalties	5,000	0
Deposits and other assets	0	23,387
Accounts payable	(33,785)	(120,266)
Accrued expenses	12,294	(31,510)
Deferred revenues	10,272	(334)
Net cash provided by (used in) operating activities	(205,790)	(578,209)
Cash flows from investing activities:
Purchase of intangible assets	0	(297,500)
Cash received in merger with emergeIT	278,709	0
Proceeds from sale of investments in available-for-sale securities	2,179	0
Net cash (used in) provided by investing activities	280,888	(297,500)
Cash flows from financing activities:
Payments on capital leases	(3,097)	(15,221)
Payments on note payable	(36,352)	(11,475)
Proceeds from the exercise of common stock warrants	180,000	375,000
Net cash provided by financing activities	140,551	348,304
Net change in cash and cash equivalents	215,649	(527,405)
Cash and cash equivalents, beginning of year	123,913	651,318
Cash and cash equivalents, ending of year	339,562	123,913
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Income taxes	806	975
Interest	927	634
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Issuance of previously subscribed common stock	0	25,000
Debt financing of Directors & Officers Insurance	30,000	35,677
Preferred and common stock and warrants to purchase stock related to emergeIT merger	$ 14,139,000	$ 0